Inhibrx Expands HexAgon Phase 2 with 50 HPV+ Patients, Targets Accelerated Approval by 2028/2029
INBX has more than doubled off its 52-week low of $28.16.
Summary
Inhibrx's updated investor deck details a Phase 2 expansion adding 50 HPV+ HNSCC patients to pursue accelerated approval by 2028/2029, plus new ozekibart colorectal and Ewing sarcoma data.
Key Events · Product Development and Regulatory · INBX
-
HexAgon Phase 2 Expansion for HPV+ HNSCC
The study amendment adds 50 HPV+ patients with PD-L1 CPS ≥1 (lowered from ≥20), targeting a potential accelerated approval path by end of 2028 or early 2029 based on the 80% vs 33% ORR advantage over pembrolizumab alone.
-
New Ozekibart Colorectal Data
Phase 1/2 ozekibart + FOLFIRI in heavily pre-treated colorectal adenocarcinoma showed 87% disease control rate, 20% objective response rate, 5.5 months median PFS, and 42% of patients progression-free at 6 months.
-
Updated Ewing Sarcoma Expansion Cohort
Ozekibart + irinotecan/temozolomide in 31 evaluable Ewing sarcoma patients achieved 87.1% disease control rate and 64.5% objective response rate, with recruitment ongoing.
-
Financial Position as of August 6, 2026
Company reported $219.5 million in cash and cash equivalents, 14.7 million common shares outstanding, and 19.7 million fully diluted shares including option reserves and warrants.
Analysis · INBX · Life Sciences
An updated investor presentation from Inhibrx reveals a material expansion of the HexAgon Phase 2 trial: 50 additional HPV+ head and neck cancer patients will be enrolled, with the PD-L1 CPS threshold lowered from ≥20 to ≥1. The company explicitly frames this as a potential path to accelerated approval by end of 2028 or early 2029, citing the 80% vs 33% objective response rate in HPV+ patients as the basis. The presentation also discloses new Phase 1/2 colorectal data for ozekibart (87% disease control rate, 20% ORR) and updated Ewing sarcoma data (64.5% ORR), broadening the clinical dataset beyond the September 8 HNSCC readout. This is the first time the company has publicly quantified the accelerated-approval strategy and the expanded enrollment design.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 29.4% of the 1487 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INBX was trading at $101.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $28.16 to $155.29. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.